Cormedix Drug Patent Portfolio
Cormedix owns 1 orange book drug protected by 4 US patents Given below is the list of Cormedix's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11738120 | Synthesis of taurolidine, purity profiles and polymorphs | 15 Apr, 2042 | Active |
| US7696182 | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin | 16 May, 2025 | Active |
| US8541393 | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin | 02 Nov, 2024 | Active |
| US9339036 | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin | 02 Nov, 2024 | Active |
Latest Legal Activities on Cormedix's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Cormedix.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Term Extension Application under 35 USC 156 Filed | 08 Jan, 2024 | US7696182 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 04 Oct, 2023 | US9339036 |
| Recordation of Patent eGrant | 29 Aug, 2023 | US11738120 |
| Mail Patent eGrant Notification | 29 Aug, 2023 | US11738120 |
|
Email Notification
Critical
| 29 Aug, 2023 | US11738120 |
|
Recordation of Patent Grant Mailed
Critical
| 29 Aug, 2023 | US11738120 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 29 Aug, 2023 | US11738120 |
| Patent eGrant Notification | 29 Aug, 2023 | US11738120 |
|
Email Notification
Critical
| 10 Aug, 2023 | US11738120 |
|
Electronic Review
Critical
| 10 Aug, 2023 | US11738120 |
|
Issue Notification Mailed
Critical
| 09 Aug, 2023 | US11738120 |
|
Application Is Considered Ready for Issue
Critical
| 02 Aug, 2023 | US11738120 |
| Dispatch to FDC | 02 Aug, 2023 | US11738120 |
| Printer Rush- No mailing | 21 Jul, 2023 | US11738120 |
|
Pubs Case Remand to TC
Critical
| 18 Jul, 2023 | US11738120 |
Cormedix's Family Patents
Cormedix Drug List
Given below is the complete list of Cormedix's drugs and the patents protecting them.
1. Defencath
Defencath is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11738120 | Synthesis of taurolidine, purity profiles and polymorphs |
15 Apr, 2042
(17 years from now)
| Active |
| US7696182 | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin |
16 May, 2025
(6 months from now)
| Active |
| US8541393 | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin |
02 Nov, 2024
(16 days from now)
| Active |
| US9339036 | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin |
02 Nov, 2024
(16 days from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Defencath's drug page